Veloxis Pharmaceuticals anticipates 2019 total revenues to be in the range of USD 58–68 million and 2019 operating income before accounting for stock compensation to be in the range of USD 4–10 million. Our outlook for 2018 as disclosed in our June 30, 2018 quarterly report anticipated revenues to be in the range of USD 36–42 million and operating loss before stock compensation to be in the range of USD 2–6 million. Actual revenues for 2018 were USD 39 million, and actual operating loss before accounting for stock compensation was USD 2 million.
The Company’s Board of Directors and Executive Management have reviewed the Company’s financial projections, taking into account matters such as the progress of Envarsus in the US and European markets, the ongoing expenses associated with sales, marketing, product support, development and the administration of the Company. On that basis, the Board of Directors and Executive Management have come to the conclusion that the Company’s funding arrangements are sufficient to meet its funding requirement through the period until cash flows generated by its operations are sufficient to cover its expenses and payment of the Athyrium note.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain statements and documents found on this website may contain "forward-looking statements." Words such as "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "future," "likely," "may," "should," "will" and similar references to future periods identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to, the following:
- statements of targets, plans, objectives or goals for future operations;
- statements containing projections of or targets for revenues, costs, income (or loss), and other financial measures;
- statements regarding future economic performance, future actions and outcome of contingencies;
- statements regarding the assumptions underlying or relating to such statements.
On this website, examples of forward-looking statements can be found under the heading Outlook and elsewhere.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements.
For an overview of some, but not all, of the risks that could adversely affect Veloxis’s results or the accuracy of forward-looking statements on this website, reference is made to the overview of risk factors in the Risk Management section on pp. 32-33 of Veloxis’s 2018 Annual Report.
Any forward-looking statement made by us on this website is based only on information currently available to us and speaks only as of the date on which it is made. Unless required by law, Veloxis is under no duty and undertakes no obligation to update or revise any forward-looking statement following publication on this website whether as a result of new information, future developments or otherwise.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about ENVARSUS XR?
ENVARSUS XR can cause serious side effects, including:
Increased risk of cancer. People who take ENVARSUS XR have an increased risk of getting some kinds of cancer, including skin and lymph gland cancer (lymphoma).
Increased risk of infection. ENVARSUS XR is a medicine that affects your immune system. ENVARSUS XR can lower the ability of your immune system to fight infections. Serious infections can happen in people receiving ENVARSUS XR that can cause death.
Call your healthcare provider right away if you have symptoms of an infection such as:
- cough or flu-like symptoms
- warm, red, or painful areas on your skin
- sweats or chills
- muscle aches
What is ENVARSUS XR?
ENVARSUS XR is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant.
ENVARSUS XR is an extended-release tablet and is not the same as tacrolimus extended-release capsules, tacrolimus immediate-release capsules or tacrolimus for oral suspension. Your healthcare provider should decide what medicine is right for you.
Who should not take ENVARSUS XR?
Do not take ENVARSUS XR if you are allergic to tacrolimus or any of the ingredients in ENVARSUS XR. See the end of this leaflet for a complete list of ingredients in ENVARSUS XR.
What should I tell my healthcare provider before taking ENVARSUS XR?
Before you take ENVARSUS XR, tell your healthcare provider if you:
- plan to receive any live vaccines. Ask your healthcare provider if you are not sure if your vaccine is a live vaccine.
- have or have had liver, kidney or heart problems.
- have any other medical conditions.
- are pregnant or plan to become pregnant. ENVARSUS XR may harm your unborn baby.
- If you are able to become pregnant, you should use effective birth control before and during treatment with ENVARSUS XR. Talk to your healthcare provider about birth control methods that may be right for you.
- Males who have female partners that are able to become pregnant should also use effective birth control before and during treatment with ENVARSUS XR. Talk to your healthcare provider before starting treatment with ENVARSUS XR about birth control methods that may be right for you.
- are breastfeeding or plan to breastfeed. ENVARSUS XR passes into your breast milk. You and your healthcare provider should decide if you will breastfeed while taking ENVARSUS XR.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, natural, herbal or nutritional supplements.
ENVARSUS XR may affect the way other medicines work, and other medicines may affect how ENVARSUS XR works.
How should I take ENVARSUS XR?
Take ENVARSUS XR exactly as your healthcare provider tells you to take it.
Your healthcare provider may change your dose of ENVARSUS XR if needed. Do not stop taking or change your dose of ENVARSUS XR without talking to your healthcare provider.
Take ENVARSUS XR once daily with fluid (preferably water) on an empty stomach, at least 1 hour before or at least 2 hours after a meal, at the same time each day (preferably in the morning).
Take ENVARSUS XR tablets whole. Do not chew, divide, crush or dissolve ENVARSUS XR tablets before swallowing. If you cannot swallow ENVARSUS XR tablets whole, tell your healthcare provider.
If you miss your dose of ENVARSUS XR, it should be taken as soon as possible, but no longer than 15 hours after missing your dose. If the time after you miss your dose is more than 15 hours, the missed dose should be skipped and the next dose should be taken the following morning at your regularly scheduled time. Do not take 2 doses at the same time.
If you take too much ENVARSUS XR, call your healthcare provider or go to the nearest hospital emergency room right away.
What should I avoid while taking ENVARSUS XR?
Live vaccines such as flu vaccine through your nose, measles, mumps, rubella, polio by mouth, BCG (TB vaccine), yellow fever, chicken pox (varicella), or typhoid.
Exposure to sunlight and UV light such as tanning machines. Wear protective clothing and use a sunscreen.
You should not eat grapefruit or drink grapefruit juice while taking ENVARSUS XR.
You should not drink alcohol while taking ENVARSUS XR.
What are the possible side effects of ENVARSUS XR?
ENVARSUS XR may cause serious side effects, including:
See “What is the most important information I should know about ENVARSUS XR?”
Problems from medication errors such as graft rejection and other serious reactions. People who take ENVARSUS XR have sometimes been given the wrong medicine because some medicines have the same ingredient (tacrolimus) as ENVARSUS XR. Check your ENVARSUS XR when you get a new prescription to make sure you have received the right medicine.
- Call your healthcare provider right away if you think you were given the wrong medicine.
- Ask your healthcare provider or pharmacist if you are not sure what ENVARSUS XR should look like.
High blood sugar (diabetes). Your healthcare provider may do certain tests to check for diabetes while you take ENVARSUS XR. Call your healthcare provider right away if you have:
- frequent urination
- fruity smell on your breath
- increased thirst or hunger
- nausea, vomiting, or stomach pain
- blurred vision
- loss of appetite
Kidney problems. Kidney problems are serious and common side effects of ENVARSUS XR. Your healthcare provider may do certain tests to check for kidney function while you take ENVARSUS XR.
Nervous system problems. Nervous system problems are a serious and common side effect of ENVARSUS XR. Call your healthcare provider right away if you get any of these symptoms while taking ENVARSUS XR. These could be signs of a serious nervous system problems:
- numbness and tingling
- vision changes
- muscle tremors
High levels of potassium in your blood. Your healthcare provider may do certain tests to check your potassium level while you take ENVARSUS XR.
High blood pressure. Your healthcare provider will monitor your blood pressure while you take ENVARSUS XR.
Changes in the electrical activity of your heart (QT prolongation).
Severe low blood cell count (anemia).
The most common side effects of ENVARSUS XR are, diarrhea, urinary tract infection, low red blood cell count (anemia), high blood pressure, and constipation.
These are not all the possible side effects of ENVARSUS XR. For more information, ask your healthcare provider or pharmacist.
Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store ENVARSUS XR?
Store ENVARSUS XR at room temperature between 68° F to 77° F (20° C to 25° C).
Safely throw away medicine that is out of date or no longer needed.
Keep ENVARSUS XR and all medicines out of reach of children.
General information about the safe and effective use of ENVARSUS XR.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ENVARSUS XR for a condition for which it was not prescribed. Do not give ENVARSUS XR to other people, even if they have the same symptoms that you have. It may harm them.
This Medication Guide summarizes the most important information about ENVARSUS XR. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about ENVARSUS XR that is written for health professionals. For more information, go to www.ENVARSUSXR.com or call 1-844-Veloxis (1-844-835-6947).
What are the ingredients in ENVARSUS XR?
Active ingredient: tacrolimus USP
Inactive ingredients: hypromellose USP, lactose monohydrate NF, polyethylene glycol NF, poloxamer NF, magnesium stearate NF, tartaric acid NF, butylated hydroxytoluene NF, and dimethicone NF
Manufactured by: Rottendorf Pharma GmbH, 59320 Ennigerloh, North Rhine-Westphalia, Germany
Marketed by: Veloxis Pharmaceuticals, Inc. 1001 Winstead Dr, Suite 310, Cary, NC 27513, United States
To report SUSPECTED ADVERSE REACTIONS, contact Veloxis Pharmaceuticals, Inc. at 1-844-VELOXIS (835-6947) or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.